NACIAM 试验:N-乙酰半胱氨酸联合硝酸酯早期用于 STEMI 直接 PCI 减少心肌梗死面积
NACIAM 为随机双盲安慰剂对照多中心研究,评估静脉高剂量 N-乙酰半胱氨酸(NAC)联合背景低剂量硝酸甘油对 112 例 STEMI 直接 PCI 患者早期心脏磁共振评估梗死面积的影响。结果显示,NAC 组梗死面积较安慰剂组绝对降低 5.5%(中位 11.0% vs 16.5%,P=0.02),心肌挽救约翻倍(60% vs 27%,P<0.01)。
要点
- NAC 联合硝酸甘油使磁共振评估梗死面积绝对降低 5.5%。
- NAC 组心肌挽救约翻倍(60% vs 27%,P<0.01)。
- 肌酸激酶曲线下面积两组差异未达统计学显著(P=0.08)。
核心结论
- 在 STEMI 直接 PCI 患者中,高剂量静脉 NAC 联合低剂量静脉硝酸甘油与梗死面积降低相关。
研究设计与样本
- 随机、双盲、安慰剂对照、多中心研究。
- 共随机 112 例 STEMI 患者,其中 75 例(NAC 组 37 例,安慰剂组 38 例)接受早期心脏磁共振检查。
- 干预为静脉高剂量 NAC(2 天共 29 g)联合背景低剂量硝酸甘油(2 天共 7.2 mg)。
主要发现
- NAC 组心脏磁共振评估梗死面积中位 11.0%(四分位距 4.1–16.3),安慰剂组 16.5%(四分位距 10.7–24.2),绝对降低 5.5%(P=0.02)。
- NAC 组心肌挽救中位 60%(四分位距 37–79),安慰剂组 27%(四分位距 14–42),P<0.01。
- NAC 组与安慰剂组肌酸激酶曲线下面积中位分别为 22 000 和 38 000 IU·h(P=0.08)。
- 缺血预处理中位时间为 2.4 小时。
临床怎么用
- 在直接 PCI 的 STEMI 患者中,可考虑高剂量静脉 NAC 联合低剂量硝酸甘油作为辅助治疗以减小梗死面积。
- 该治疗对临床心脏结局的影响尚需更大规模研究评估。
局限性
- 仅 75 例(共 112 例随机)患者完成早期心脏磁共振评估。
- 研究样本量较小,需更大规模研究评估临床结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Contemporary ST-segment-elevation myocardial infarction management involves primary percutaneous coronary intervention, with ongoing studies focusing on infarct size reduction using ancillary therapies. N-acetylcysteine (NAC) is an antioxidant with reactive oxygen species scavenging properties that also potentiates the effects of nitroglycerin and thus represents a potentially beneficial ancillary therapy in primary percutaneous coronary intervention. The NACIAM trial (N-acetylcysteine in Acute Myocardial Infarction) examined the effects of NAC on infarct size in patients with ST-segment-elevation myocardial infarction undergoing percutaneous coronary intervention. METHODS: This randomized, double-blind, placebo-controlled, multicenter study evaluated the effects of intravenous high-dose NAC (29 g over 2 days) with background low-dose nitroglycerin (7.2 mg over 2 days) on early cardiac magnetic resonance imaging-assessed infarct size. Secondary end points included cardiac magnetic resonance-determined myocardial salvage and creatine kinase kinetics. RESULTS: Of 112 randomized patients with ST-segment-elevation myocardial infarction, 75 (37 in NAC group, 38 in placebo group) underwent early cardiac magnetic resonance imaging. Median duration of ischemia pretreatment was 2.4 hours. With background nitroglycerin infusion administered to all patients, those randomized to NAC exhibited an absolute 5.5% reduction in cardiac magnetic resonance-assessed infarct size relative to placebo (median, 11.0%; [interquartile range 4.1, 16.3] versus 16.5%; [interquartile range 10.7, 24.2]; P=0.02). Myocardial salvage was approximately doubled in the NAC group (60%; interquartile range, 37-79) compared with placebo (27%; interquartile range, 14-42; P<0.01) and median creatine kinase areas under the curve were 22 000 and 38 000 IU·h in the NAC and placebo groups, respectively (P=0.08). CONCLUSIONS: High-dose intravenous NAC administered with low-dose intravenous nitroglycerin is associated with reduced infarct size in patients with ST-segment-elevation myocardial infarction undergoing percutaneous coronary intervention. A larger study is required to assess the impact of this therapy on clinical cardiac outcomes. CLINICAL TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry. URL: http://www.anzctr.org.au/. Unique identifier: 12610000280000.
引用
- Pasupathy S, Tavella R, Grover S, et al. Early Use of N-acetylcysteine With Nitrate Therapy in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction Reduces Myocardial Infarct Size (the NACIAM Trial [N-acetylcysteine in Acute Myocardial Infarction]). Circulation. 2017. PMID: 28634219. doi:10.1161/CIRCULATIONAHA.117.027575
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。